148 related articles for article (PubMed ID: 32333847)
1. Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.
Skoura N; Wang-Jairaj J; Della Pasqua O; Chandrasekaran V; Billiard J; Yeakey A; Smith W; Steel H; Tan LK
Lancet Infect Dis; 2020 Aug; 20(8):983-991. PubMed ID: 32333847
[TBL] [Abstract][Full Text] [Related]
2. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.
Wright JG; Plikaytis BD; Rose CE; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Semenova VA; Li H; Schiffer J; Dababneh H; Martin SK; Martin SW; Marano N; Messonnier NE; Quinn CP
Vaccine; 2014 Feb; 32(8):1019-28. PubMed ID: 24373307
[TBL] [Abstract][Full Text] [Related]
3. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.
Marano N; Plikaytis BD; Martin SW; Rose C; Semenova VA; Martin SK; Freeman AE; Li H; Mulligan MJ; Parker SD; Babcock J; Keitel W; El Sahly H; Poland GA; Jacobson RM; Keyserling HL; Soroka SD; Fox SP; Stamper JL; McNeil MM; Perkins BA; Messonnier N; Quinn CP;
JAMA; 2008 Oct; 300(13):1532-43. PubMed ID: 18827210
[TBL] [Abstract][Full Text] [Related]
4. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Hopkins RJ; Daczkowski NF; Kaptur PE; Muse D; Sheldon E; LaForce C; Sari S; Rudge TL; Bernton E
Vaccine; 2013 Jun; 31(30):3051-8. PubMed ID: 23701746
[TBL] [Abstract][Full Text] [Related]
6. Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans.
Schiffer JM; Chen L; Dalton S; Niemuth NA; Sabourin CL; Quinn CP
Vaccine; 2015 Jul; 33(31):3709-16. PubMed ID: 26072016
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.
Ionin B; Hopkins RJ; Pleune B; Sivko GS; Reid FM; Clement KH; Rudge TL; Stark GV; Innes A; Sari S; Guina T; Howard C; Smith J; Swoboda ML; Vert-Wong E; Johnson V; Nabors GS; Skiadopoulos MH
Clin Vaccine Immunol; 2013 Jul; 20(7):1016-26. PubMed ID: 23658392
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study.
Kang CK; Kim NH; Kim CJ; Rhie GE; Jo SK; Ahn M; Kang J; Choe PG; Park WB; Kim NJ; Oh MD
Vaccine; 2019 Jun; 37(29):3820-3824. PubMed ID: 31151800
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.
Pondo T; Rose CE; Martin SW; Keitel WA; Keyserling HL; Babcock J; Parker S; Jacobson RM; Poland GA; McNeil MM
Vaccine; 2014 Jun; 32(28):3548-54. PubMed ID: 24768633
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of raxibacumab in healthy adult subjects.
Oosterholt SP; Della Pasqua O
Br J Clin Pharmacol; 2021 Dec; 87(12):4718-4725. PubMed ID: 33973655
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.
King JC; Gao Y; Quinn CP; Dreier TM; Vianney C; Espeland EM
Vaccine; 2015 May; 33(21):2470-6. PubMed ID: 25850022
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
[TBL] [Abstract][Full Text] [Related]
15. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
Krishnan V; Andersen BH; Shoemaker C; Sivko GS; Tordoff KP; Stark GV; Zhang J; Feng T; Duchars M; Roberts MS
Clin Vaccine Immunol; 2015 Apr; 22(4):430-9. PubMed ID: 25673303
[TBL] [Abstract][Full Text] [Related]
18. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
Welkos S; Little S; Friedlander A; Fritz D; Fellows P
Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
20. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.
Campbell JD; Clement KH; Wasserman SS; Donegan S; Chrisley L; Kotloff KL
Hum Vaccin; 2007; 3(5):205-11. PubMed ID: 17881903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
